SCHEMBL4760981

SCHEMBL4760981

Cc1ccc(F)cc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 10/20 0.76
AXL P30530 10/20 0.76
MAP4K2 Q12851 10/20 0.76
STK3 Q13188 10/20 0.76
SLK Q9H2G2 10/20 0.76
MKNK2 Q9HBH9 10/20 0.76
LCK P06239 10/20 0.76
PLK4 O00444 9/20 0.76
MARK3 P27448 9/20 0.76
BLK P51451 9/20 0.76
MARK2 Q7KZI7 9/20 0.76
CLK4 Q9HAZ1 9/20 0.76
AURKA O14965 9/20 0.76
MINK1 Q8N4C8 8/20 0.76
LIMK1 P53667 8/20 0.76
MAP4K5 Q9Y4K4 8/20 0.76
CDK1 P06493 7/20 0.76
BRSK1 Q8TDC3 7/20 0.76
SRPK1 Q96SB4 7/20 0.76
MET P08581 7/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720448 0.89 PLK4 (0.69) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL4761640 0.88 PLK4 (0.81) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL5469090 0.87 KDR (0.76) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL4722423 0.86 PLK4 (1.00) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL5469023 0.85 KDR (0.78) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL4721626 0.84 STK3 (0.78) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL4722113 0.84 MARK3 (0.78) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL5472353 0.84 KDR (1.00) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL4762855 0.83 KDR (1.00) MAP4K4AXLMAP4K2STK3SLK
SCHEMBL5474949 0.82 MAP4K4 (0.78) MAP4K4AXLMAP4K2STK3SLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968979-A2 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2008-09-17 EP disclosed
WO-2007067781-A2 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2007-06-14 WO disclosed
US-20070135387-A1 Inhibitors of protein kinases ABBOTT LABORATORIES 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135387-A1 Inhibitors of protein kinases MAP3K20, PACSIN2, MAP4K2 MAP4K4 31/4885AXL 1486/4885MAP4K2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.